Stocks to Watch Today, 17th March 2025: IndusInd Bank, Infosys, Wipro, IRFC, and more

The Indian equity markets are poised for a dynamic trading session today, 17th March 2025, following an extended break for the Holi festival and the weekend. Investors will be factoring in global market movements and a raft of company-specific announcements as the trading week commences. The previous trading session on 13th March saw both the Sensex and the Nifty50 close in negative territory, slipping by 0.27% to 73,828.91 and 0.33% to 22,397.20 respectively.

Key Stocks in Focus

IndusInd Bank: The Reserve Bank of India (RBI) has moved to address speculation surrounding IndusInd Bank’s financial stability, affirming its robust financial position. The central bank highlighted the bank’s Capital Adequacy Ratio of 16.46% and a Provision Coverage Ratio of 70.20% for the quarter ending December 2024. Additionally, the bank’s Liquidity Coverage Ratio stands at a healthy 113%, indicating overall financial soundness.

Infosys: Infosys McCamish Systems, a subsidiary of Infosys, has reached a settlement in the United States regarding six class-action lawsuits stemming from a cyber incident in November 2023. The settlement, amounting to $17.5 million, was achieved through mediation on 13th March 2025.

Wipro: IT major Wipro is undertaking a restructuring of its Global Business Lines (GBLs) with the aim of strengthening its focus on key areas such as artificial intelligence, cloud computing, and digital transformation. This strategic move will come into effect on 1st April 2025, intending to streamline operations and better align with evolving client requirements.

Indian Railway Finance Corporation (IRFC): IRFC has scheduled a board meeting for today, 17th March, to consider the declaration of a second interim dividend for the financial year 2024-25. The company has set 21st March as the record date to identify shareholders eligible for the dividend.

NMDC: Mining corporation NMDC has also convened a board meeting today, 17th March, to consider an interim dividend for the financial year 2024-25. In adherence to SEBI’s insider trading regulations, the company has initiated a trading window closure until 19th March.

Power Grid Corporation: State-owned Power Grid Corporation has approved investments totalling ₹341.57 crore for two new transmission projects. These projects are aimed at facilitating power evacuation from the Ratle (850 MW) and Kiru (624 MW) hydroelectric projects located in Jammu and Kashmir, with an expected completion timeline of mid-2026.

Tejas Networks: Tejas Networks, a telecom gear manufacturer, has received a financial incentive of ₹123.45 crore from the Ministry of Communications under the Production-Linked Incentive (PLI) Scheme for the financial year 2023-24. This incentive is expected to support the company’s growth and manufacturing expansion.

Zydus Lifesciences: Zydus Lifesciences’ API Unit 1 situated in Ankleshwar, Gujarat, has successfully cleared a US Food and Drug Administration (USFDA) inspection without any observations. This outcome reaffirms the company’s adherence to international regulatory standards. Additionally, the company has received final USFDA approval to manufacture and market Eluxadoline Tablets.

Brigade Enterprises: Real estate developer Brigade Enterprises has launched its latest residential venture, Brigade Eternia, in Yelahanka, Bengaluru. The project, spanning 14.65 acres and comprising 1,124 residential units, has an estimated revenue potential exceeding ₹2,700 crore with a projected completion date of 31st March 2030. The company has also launched another premium joint venture residential project, “Ebony at Brigade Orchards,” in Devanahalli, Bengaluru.

GR Infraprojects: Infrastructure company GR Infraprojects has secured the Agra-Gwalior Greenfield Road project valued at ₹4,262.78 crore. Awarded by the National Highways Authority of India (NHAI), the project will be developed under the Build-Operate-Transfer (BOT) toll model.

Shilpa Medicare: Shilpa Pharma Lifesciences Ltd, a wholly-owned subsidiary of Shilpa Medicare, has successfully completed a USFDA inspection at its Unit-2 facility in Raichur with zero observations. The inspection, conducted from 10th to 14th March 2025, concluded without the issuance of any Form 483, marking the second consecutive clean inspection for the site.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.